An estimated 73,000 new cases of Cervical Cancer are reported in Indian Women and the incidence is reported to about 1,32,000 cases annually, which is 30% of the total 4,70,000 new cases reported every year, said WHO.
These deaths owing to the cervical cancer cause are largely preventable and are likely to significantly reduce the cost burden of disease, delivering a health society.
A recent study that shows that “Mass-ARRAY spectrometry is more sensitive than existing technologies for type specific detection of high risk oncogenic HPV ( Human Papilloma Virus) genotypes in cervical cancer.”
Commenting on the study, Dr. Partha Basu, Head, Department of Gynecologic Oncology at CNCI hospital Kolkata states, “ The study confirms, the MassARRAY technology and the current panel has the advantage of both sensitivity and providing information about the high risk genotype of the HPV causing cervical cancer.”
Technical expert and Co-Author and in the study, Dr. Puneet Chandna, Managing Director of AceProbe Technologies (I) Pvt. Ltd. said, “This breakthrough research could not have been achieved without a collaborative mode under the Public Private Partnership scheme.”